Serotonin central synaptic transmission and the regulation of the extrapyramidal system: The psychiatric perspective

Human Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages

  Ring, Howard ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DRUG DEPENDENCE; EXTRAPYRAMIDAL SYSTEM; GILLES DE LA TOURETTE SYNDROME; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; OBSESSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; SYNAPTIC TRANSMISSION;

EID: 0029790909     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199606)11:2+3.0.CO;2-D     Document Type: Review

References (95)

1. Anonymous. (1995). British National Formulary-Number 30. The Pharmaceutical Press, London.
2. Agid, Y., Javoy-Agid, F. and Ruberg, M. (1987). Biochemistry of neurotransmitters in Parkinson's disease. In: Movement Disorders 2, Marsden, C. D. and Fahn, S. (Eds), Butterworths, London, pp. 166-230.
3. Akil, M., Schwartz, J. A., Dutchak, D., Yuzbasiyan-Gurkan, V. and Brewer, G. J. (1991). The psychiatric presentations of Wilson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 3, 377-382.
4. Alexander, G. E., DeLong, M. R. and Strick, P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience, 9, 357-381.
5. Baldessarini, R. J. and Marsh, E. (1990). Fluoxetine and side effects. Archives of General Psychiatry, 47, 191-192.
6. Baldwin, D., Fineberg, N. and Montgomery, S. (1991). Fluoxetine, fluvoxamine and extrapyramidal tract disorders. International Clinical Psychopharmacology, 6, 51-58.
7. Bennet, J. P., Enna, S. J., Bylund, D., Gillin, J. C. and Snyder, S. H. (1979). Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry, 36, 927-934.
8. Besson, M. J., Cheramy, A., Feltz, P. and Glowinski, J. (1969). Release of newly synthesized dopamine from dopamine-containing terminals in the striatum of the rat. Proceedings of the National Academy of Sciences of the USA, 62, 741-748.
9. Bouchard, R. H., Pourcher, E. and Vincent, P. (1989). Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry, 146, 1352-1353.
10. Breier, A. (1995). Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research. 14, 187-202.
11. Breier, A., Buchanan, R. W., Kirkpatrick, B., Davis, O. R., Irish, D., Summerfelt, A. and Carpenter, W. T. J. (1994). Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20-26.
12. Caley, C. F. and Friedman, J. H. (1996). Does fluoxetine exacerbate Parkinson's disease? Journal of Clinical Psychiatry, 53, 278-282.
13. Carboni, E., Acquas, E., Frau, R. and Di Chiara, G. (1989). Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. European Journal of Pharmacology, 164, 515-519.
14. Carlsson, A. and Lindqvist, M. (1963). Effect of chlorpromazine and haloperidol on formation of methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologia et Toxicologia, 20, 140-144.
15. Chadwick, D., Reynolds, E. H. and Marsden, C. D. (1976). Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics, Journal of Neurology, Neurosurgery and Psychiatry, 39, 1210-1218.
16. Cloninger, C. R. (1987), Neurogenetic adaptive mechanisms in alcoholism. Science, 236, 410-416.
17. Cloninger, C. R. (1995). The psychobiological regulation of social cooperation. Nature Medicine, 1, 623-625.
18. Costall, B. and Naylor, R. J. (1992). The Psychopharmacology of 5-HT3 receptors. Pharmacology & Toxicology, 71, 401-415.
19. Creese, I. and Iverson, S. D. (1974). The role of forebrain dopamine systems in amphetamine-induced stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Psychopharmacology, 39, 345-357.
20. Cummings, J. L. (1992). Depression and Parkinson's disease: A review. American Journal of Psychiatry, 149, 443-454.
21. Cummings, J. L. (1993). Frontal-subcortical circuits and human behavior. Archives of Neurology, 50, 873-880.
22. Di Chiara, G., Acquas, E. and Carboni, E. (1991). Role of mesolimbic dopamine in the motivational effects of drugs: brain dialysis and place preference studies. In: The mesolimbic dopamine system: from motivation to action, Willner, P. and Scheel-Kruger, J. (Eds), John Wiley and Sons, Chichester, pp. 368-384.
23. Essman, W. D., Singh, A. and Lucki, I. (1994). Serotonergic properties of cocaine: effects on a 5-HT2 receptor-mediated behavior and on extracellular concentrations of serotonin and dopamine. Pharmacology Biochemistry and Behavior, 49, 107-113.
24. Farde, L., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C. and Ericsson, B. (1995). Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. Journal of Clinical Psychopharmacology, 15 (Suppl. 1), 19S-23S.
25. Fibigier, H. C. (1984). The neurobiological substrates of depression in Parkinson's disease: A hypothesis. Canadian Journal of Neurological Sciences, 11, 105-107.
26. Fiorino, D. F. Coury, A., Fibiger, H. C. and Phillips, A. G. (1993). Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behavioural Brain Research, 55, 131-141.
27. Fishbain, D. A., Dominguez, M., Goldberg, M., Olsen, E. and Rosomoff, H. (1992). Dyskinesia associated with fluoxetine use. Neuropsychiatry, Neuropsychology, and Behavioural Neurology, 5, 97-100.
28. Folstein, S. E., Abbott, M. H., Chase, G. A., Jensen, B. A. and Folstein, M. F. (1983). The association of affective disorder with Huntington's disease in a case series and in families. Psychological Medicine, 13, 537-542.
29. Gelders, Y. G. (1989). Thymosthenic agents, a novel approach in the treatment of schizophrenia. British Journal of Psychiatry, 155 (Suppl. 5), 33-36.
30. Goldman-Rakic, P. F. (1988). Topography of cognition: parallel distributed networks in primate association cortex. Annual Review of Neuroscience, 11, 137-156.
31. Goodman, W. K., McDougle, C. J., Price, L. H., Riddle, M. A., Pauls, D. L. and Leckman, J. F. (1990). Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder. Journal of Clinical Psychiatry, 51 (Suppl.), 36-43.
32. Grant, K. A. (1995). The role of 5-HT3 receptors in drug dependence. Drug and Alcohol Dependence, 38, 155-171.
33. Graybiel, A. M. (1991). Neurotransmitters and neuromodulators in the basal ganglia. Trends in Neurosciences, 14, 244-254.
34. Hadzovic, S. and Ernst, A. M. (1969). The effect of 5-hydroxytryptamine and 5-hydroxytryptophan on extrapyramidal function. European Journal of Pharmacology, 6, 90-95.
35. Huang, X. and Nichols, D. E. (1993). 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. European Journal of Pharmacology, 238, 291-296.
36. Hyttel, J. (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 9 (Suppl. 1), 19-26.
37. Imperato, A. and Angelucci, L. (1989). 5HT3 receptors control dopamine release in the nucleus accumbens of freely moving rats. Neuroscience Letters, 101, 214-218.
38. Insel, T. R. (1992). Toward a neuroanatomy of obsessive - compulsive disorder. Archives of General Psychiatry, 49, 739-744.
39. Jacobsen, F. M. (1995). Risperidone in the treatment of affective illness and obsessive - compulsive disorder. Journal of Clinical Psychiatry. 56, 423-429.
40. Joyce, J. N. (1993). The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology, 112, S16-S34.
41. Kahn, R. S. and Davidson, M. (1993). Serotonin, dopamine and their interactions in schizophrenia. Psychopharmacology, 112, S1-S4.
42. Kalivas, P. W. (1993). Neurotransmitter regulation of dopamine neurones in the ventral tegmental area. Brain Research Reviews, 18, 75-113.
43. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. and the clozapine collaborative study group (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
44. Kane, J. M. and Freeman, H. L. (1994). Towards more effective antipsychotic treatment. British Journal of Psychiatry, 165 (Suppl. 25), 22-31.
45. Kerwin, R. W. (1994). The new atypical antipsychotics. British Journal of Psychiatry, 164, 141-148.
46. Korsgaard, S., Noring, U., Povlsen, U. J. and Gerlach, J. (1986). Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clinical Neuropharmacology, 9, 52-57.
47. Kuczenski, R., Segal, D. S., Cho, A. K. and Melega, W. (1995). Hippocampus norepenephrine, caudate dopamine and serotonin, and behavioral responses to stereoisomers of amphetamine and methamphetamine. Journal of Neuroscience, 15, 1308-1317.
48. Lane, R. J. M. and Routledge, P. A. (1983). Drug-induced neurological disorders. Drugs, 26, 124-147.
49. Lindenmayer, J. P. (1995). New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatrica Scandinavica, 91 (Suppl. 388), 15-19.
50. Lishman, W. A. (1987). Organic Psychiatry, 2nd edn. Blackwell Scientific Publications, Oxford.
51. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's syndrome. American Journal of Psychiatry, 152, 1359-1361.
52. Marder, S. R. and Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
53. Marsh, G. G. and Markham, C. H. (1973). Does levodopa alter depression and psychopathology in Parkinsonism patients? Journal of Neurology Neurosurgery and Psychiatry, 36, 925-935.
54. Mayeux, R. (1990). The 'serotonin hypothesis' for depression in Parkinson's disease. In: Advances in Neurology, Vol. 53: Parkinson's Disease: Anatomy, Pathology and Therapy, Streifler, M. B., Korczyn, A. D., Melamed, E. and Youmid, M. B. H. (Eds), Raven Press, New York, pp. 163-166.
55. Mayeux, R., Stern, Y., Cote, L. and Williams, J. B. W. (1984). Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology, 34, 642-646.
56. Mayeux, P., Stern, Y., Williams, J. B. W., Cote, L., Frantz, A. and Dyrenfurth, I. (1986). Clinical and biochemical features of depression in Parkinson's disease. American Journal of Psychiatry, 143, 756-1759.
57. McDougle, C. J., Fleischmann, R. L., Epperson, C. N., Wasylink, S., Leckman, J. F. and Price, L. H. (1995). Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. Journal of Clinical Psychiatry, 56, 526-528.
58. Meltzer, H. Y. (1989). Clinical studies on the mechanism of action of clozapine. The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology, 99, S18-S27.
59. Meltzer, H. Y. (1995). The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. Journal of Clinical Psychopharmacology, 15 (Suppl. 1), 2S-3S.
60. Meltzer, H. Y., Matsubara, S. and Lee, J. (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. Journal of Pharmacology and Experimental Therapeutics, 251, 238-246.
61. Meltzer, H. Y., Young, M., Metz, J., Fang, V. S., Schyve, P. M. and Arora, R. C. (1979). Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. Journal of Neural Transmission, 45, 165-175.
62. Menza, M. A., Forman, N. E., Sage, J. I. and Golbe, L. I. (1993). Parkinson's disease and smoking: the relationship to personality. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 6, 214-218.
63. Menza, M. A. and Mark, M. H. (1994). Parkinson's disease and depression: The relationship to disability and personality. Journal of Neuropsychiatry and Clinical Neurosciences, 6, 165-169.
64. Mesulam, M. (1990). Large-scale neurocognitive networks and distributed processing for attention, language and memory. Annals of Neurology, 28, 597-613.
65. Milson, J. A. and Pycock, C. J. (1976). Effects of drugs acting on cerebral 5-hyroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice. British Journal of Pharmacology, 56, 77-85.
66. Nauta, H. J. W. (1986). The relationship of the basal ganglia to the limbic system. In: Handbook of Clinical Neurology, Vol. 5 (49): Extrapyramidal Disorders, Vinken, P. J., Bruyn, G. W. and Klawans, H. L. (Eds), Elsevier Science Publishers, Amsterdam, pp. 19-31.
67. Nordstrom, A. L., Farde, L., Nyberg, S., Karlsson, P., Halldin, C. and Sedvall, G. (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry, 152, 1444-1449.
68. Pauls, D. L. and Leckman, J. F. (1986). The inheritance of Gilles de la Tourette syndrome and associated behaviors. New England Journal of Medicine, 315, 993-997 (abstract).
69. Pauls, D. L., Towbin, K. E., Leckman, J. F., Jahner, G. E. P. and Cohen, D. J. (1986). Gilles de la Tourette's syndrome and obsessive-compulsive disorder: Evidence supporting a genetic relationship. Archives of General Psychiatry, 43, 1180-1182.
70. Peroutka, S. J. and Snyder, S. H. (1980). Relationship of neuroleptic drug effects to brain dopamine, serotonin, adrenergic and histamine receptors and clinical potency. American Journal of Psychiatry, 137, 1518-1523.
71. 3H]-paroxetin binding sites in putamen. Neurology, 36, 556-560.
72. Rapoport, J. L. (1990). Obsessive compulsive disorder and basal ganglia dysfunction. Psychological Medicine, 20, 465-469.
73. Rasmsussen, S. A. and Tsuang, M. T. (1986). Clinical characteristics and family history in DSM-111 obsessive-compulsive disorder. American Journal of Psychiatry. 143, 317-322.
74. Roberts, D. C. S., Koob, G. F., Klonoff, P. and Fibiger, H. C. (1980). Extinction and recovery of cocaine administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacology, Biochemistry and Behavior, 12, 781-787.
75. Robertson, M. (1989). The Gilles de la Tourette syndrome: the current status. British Journal of Psychiatry, 154, 147-169.
76. Rogers, D. (1985). The motor disorders of severe psychiatric illness: a conflict of paradigms. British Journal of Psychiatry, 147, 221-232.
77. Roos, R. A. C. (1993). Dopaminometic psychosis: clinical manifestations, epidemiology and risk factors. In: Mental Dysfunction in Parkinson's Disease, Wolters, A. C. and Scheltens, P. (Eds), vrije Universiteit, Amsterdam, pp. 281-284.
78. Roth, B. L., Craigo, S. C., Choudhary, M. S., Uluer, A., Monsma, F. F. J., Shen, Y., Meltzer, H. Y. and Sibley, D. R. (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine 6 (5-HT6) and 5-hydroxytryptamine 7 (5-HT7) receptors. Journal of Pharmacology and Experimental Therapeutics, 268, 1403-1410.
79. Scheel-Kruger, J. and Willner, P. (1991). The mesolimbic system: principles of operation. In: The Mesolimbic Dopamine System: From Motivation to Action, Willner, P. and Scheel-Kruger, J. (Eds), John Wiley Sons, Chichester, pp. 559-597.
80. Schiffer, R. B., Kurlan, R., Rubin, A. and Boer, S. (1988). Evidence for atypical depression in Parkinson's disease. American Journal of Psychiatry, 145, 1020-1022.
81. Schneider, J. S. (1984). Basal ganglia role in behavior: Importance of sensory gating and its relevance to psychiatry. Biological Psychiatry, 19, 1693-1709.
82. Schwartz, J. M., Stoessel, P. W., Baxter, L. R. J., Martin, K. M. and Phelps, M. E. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modiciation of obsessive-compulsive disorder. Archives of General Psychiatry, 53, 109-113.
83. Seeman, P. (1992). Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology, 7, 261-284.
84. Steur, E. R. (1993). Increase of parkinson disability after fluoxetine medication. Neurology, 43, 211-213.
85. Tiihonen, J., Kuikka, J., Bergstrom, K., Hakola, P., Karhu, J. Ryynanen, O. and Fohr, J. (1995). Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nature Medicine, 1, 654-657.
86. Trimble, M. R. (1988). Biological Psychiatry. John Wiley and Sons, Chichester.
87. Ugedo, L., Grenhoff, J. and Svensson, T. H. (1989). Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopaminergic neurones by blocking serotonergic inhibition. Psychopharmacology, 98, 45-50.
88. Van Praag, H. M. (1982). Depression, suicide and the metabolism of serotonin in the brain. Journal of Affective Disorders, 4, 275-290.
89. Van Praag, H. M. (1993). Serotonin and affective psychopathology in Parkinson's disease. A psychobiological hypothesis with therapeutic consequences. In: Mental Dysfunction in Parkinson's Disease, Wolters, E. C. and Scheltens, P. (Eds), vrije Universiteit, Amsterdam, pp. 335-3418.
90. Virkkunen, M., Kallio, E., Rawlings, R., Tokola, R., Poland, R. E., Guidotti, A., Nemeroff, C., Bisette, G., Kalogeras, K. and Karonen, S. L. (1994). Personality profiles and state aggressiveness in Finnish alcoholic, violent offenders, and healthy volunteers. Archives of General Psychiatry, 51, 28-33.
91. von Economo, C. (1931). Encephalitis lethargica (transl. K. O. Newman). Oxford University Press, Oxford.
92. Watling, K. J., Beer, M. S., Stanton, J. A. and Newberry, N. R. (1990). Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. European Journal of Pharmacology, 182, 465-472.
93. Wilson, S. A. K. (1912). Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain, 34, 295-309.
94. Wise, S. P. and Rapoport. J. L. (1989). Obsessive-compulsive disorder: Is it basal ganglia dysfunction? Obsessive-Compulsive Disorder in Children and Adolescents, Rapoport, J. L. (Ed.), American Psychiatric Press, Washington, D.C., pp. 327-344.
95. Yassa, R., Camille, Y. and Belzile, L. (1987). Tardive dyskinesia in the course of antidepressant therapy: A prevalence study and review of the literature. Journal of Clinical Psychopharmacology, 7, 243-246.